Loading
A phase 1/2 trial of I-DXd in oesophageal cancer, run by Merck Sharp & Dohme LLC, now recruiting.
A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F) is a phase 1/2 interventional study registered as NCT07405151 by Merck Sharp & Dohme LLC, with 60 participants planned, started 2026-03-27 and due to reach its primary completion in 2027-06-12. Interventions recorded: I-DXd and Rescue Medication.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Daiichi Sankyo, Merck & Co. (MSD), Oesophageal cancer and the tag pipeline.
Shares Daiichi Sankyo, Merck & Co. (MSD), Oesophageal cancer and the tag pipeline.
Shares Daiichi Sankyo, Merck & Co. (MSD), Oesophageal cancer and the tag pipeline.
Shares Daiichi Sankyo, Merck & Co. (MSD) and the tag pipeline.
Shares Daiichi Sankyo, Merck & Co. (MSD) and the tag pipeline.
Shares Daiichi Sankyo, Merck & Co. (MSD) and the tag pipeline.
Shares Daiichi Sankyo, Merck & Co. (MSD) and the tag pipeline.
Shares Daiichi Sankyo, Merck & Co. (MSD) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/